Orphan Drug Designation for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS)
- Details
- Category: Product
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) announced today that Soliris(R) (eculizumab), its first-in-class complement inhibitor, has been granted Orphan Medicinal Product Designation by the European Commission for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS).
Positive top-line results from a Phase 3 trial evaluating Vectibix (panitumumab)
- Details
- Category: Amgen
Amgen (Nasdaq: AMGN) has announced positive top-line results from a Phase 3 trial evaluating Vectibix (panitumumab) in combination with FOLFIRI (an irinotecan-based chemotherapy) as a second-line treatment in 1,186 patients
with metastatic colorectal cancer (mCRC). The co-primary endpoints, tested
independently, were progression-free and overall survival.
Pandemic (H1N1) 2009 influenza update
- Details
- Category: GlaxoSmithKline
GSK issued an update on its progress to develop a vaccine against the Pandemic (H1N1) 2009 influenza virus, and announced that it has commenced the clinical development programme for its adjuvanted pandemic vaccine. Enrolment into this first study has been completed.
Sanofi Pasteur submits supplemental application for A(H1N1) pandemic vaccine to U.S. FDA
- Details
- Category: Sanofi
Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), has submitted to the U.S. Food and Drug Administration (FDA) a supplemental application for licensure of its influenza A(H1N1) 2009 monovalent vaccine. Responding to recent recommendations by the FDA, the company's supplemental application requests the FDA's evaluation of the influenza A(H1N1) 2009 strain change, which is expected to expedite the licensure process for the pandemic vaccine.
Forest Laboratories and AstraZeneca to Co-Develop and Commercialize a Next Generation Anti-Infective
- Details
- Category: Business
Forest Laboratories (NYSE:FRX) and AstraZeneca (NYSE:AZN) have entered into a definitive collaboration agreement to co-develop and commercialize ceftaroline in all markets outside the United States, Canada and Japan. Ceftaroline is Forest's late stage, next generation cephalosporin being investigated for the treatment of complicated skin and skin structure infections (cSSSI) and community-acquired bacterial pneumonia (CABP).
Studies Highlight Potential New Option in the Treatment of Bone Loss
- Details
- Category: Amgen
Amgen Inc. (Nasdaq: AMGN) has announced the publication of results from two pivotal Phase 3 studies investigating the safety and effectiveness of denosumab at reducing fracture risk in more than 7,800 women with postmenopausal osteoporosis and in more than 1,400 men with non-metastatic prostate cancer undergoing androgen deprivation therapy (ADT) leading to bone loss.
Sandoz launches first generic version of Prograf® capsules
- Details
- Category: Novartis
Sandoz has announced the introduction of tacrolimus capsules, a generic equivalent of Prograf®, in the US. Tacrolimus is an immunosuppressive treatment used to help prevent rejection of a kidney or liver transplant.
More Pharma News ...
- Abbott Partners With Beech-Nut to Provide New Parents with Nutrition Education and Support
- Nycomed and Forest Laboratories to collaborate on US commercialisation of Daxas® in COPD
- Boehringer Ingelheim to commence Phase III study investigating the role of BIBW 2992 (Tovok)
- President Clinton, Pfizer, and Mylan Announce New Agreements to Lower Prices of Medicines
- Effient(TM) is Now Available in Pharmacies
- Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor (TNF) Blockers
- AstraZeneca And Astellas Enter Agreement for Co-Promotion of Symbicort Turbuhaler in Japan